

Brand Name	Study Name	Efficacy (95% CI)	Cytokine Release Syndrome	Neurotoxicity	Other Notable Toxicities
Abecma	KarMMA	ORR - 73%; CR - 33% Median DOR - 10.7 months, 19 months in responders Median PFS - 8.8 months, 20.2 months in responders Median OS - 19.4 months, 78% at 12 months	Any grade - 84%; Grade 3 or 4 - 5% Median time to onset - 1 day Median duration - 5 days Tocilizumab use - 52%; Glucocorticoid use - 15%	Any grade - 18%; Grade 3 - 3% Median time to onset - 2 days Median duration - 3 days	Neutropenia (91%), anemia (70%), and thrombocytopenia (63%)
Breyanzi	TRANSCEND	ORR - 73%; CR - 53% Median DOR - data not reached Median PFS - 6.8 months, 44.1% at 12 months Median OS - 21.1 months, 58% at 12 months	Any grade - 42%; Grade 3 or higher - 2% Median time to onset - 5 days Median duration - 5 days Tocilizumab use - 10%; Glucocorticoid use - 2% Both - 8%	Any grade - 30%; Grade 3 or higher - 10% Median time to onset - 9 days Median duration - 11 days	Prolonged cytopenia's (37%), hypogammaglobulinemia (14%), and grade 3 or worse infections (12%)
Kymriah	JULIET	ORR - 52%; CR - 40% Median DOR - data not reached Median PFS - not reached, estimated 83% at 12 months Median OS - 12 months, estimated 49% at 12 months	Any grade - 58%; Grade 3 or 4 - 22% Median time to onset - 3 days Median duration - 7 days Tocilizumab use - 14%; Both - 10%	Any grade - 21%; Grade 3 or 4 - 12% Median time to onset - 6 days Median duration - 14 days	Infection (34%), cytopenia's (44%), febrile neutropenia (15%), tumor lysis syndrome (1%)
	Maude, et al.	ORR: 81% RFS rate - 80% at 6 months, 59% at 12 months Rate of Event-free Survival - 73% at 6 months, 50% at 12 months Rate of OS: 90% at 6 months, 76% at 12 months	Any grade - 77% Median time to onset - 3 days Median duration - 8 days Tocilizumab use - 37%	Any grade - 40%; Grade 3 - 13% 50% resolved within 10 days 75% resolved within 18 days	Infection (43%), cytopenia's (37%), febrile neutropenia (35%), tumor lysis syndrome (4%)
Tecartus	ZUMA-2	ORR - 93% per protocol, 85% ITT; CR - 67% per protocol, 59% ITT Median DOR - data not reached PFS - 61% at 12 months OS - 83% at 12 months	Any grade - 91%; Grade 3 or higher - 15% Median time to onset - 2 days Median duration - 11 days Tocilizumab use - 59%; Glucocorticoid use - 22%; Vasopressor use - 16%	Any grade - 63%; Grade 3 or higher - 31% Median time to onset - 7 days Median duration - 12 days	Grade 3 or higher cytopenia's (94%) and infections (32%)
	ZUMA-3	ORR - 71%; CR - 56% Median DOR - 12.8 months Median RFS- 11.6 months in all, 14.3 months in responders, 58% OS - 18.2 months, 71% at 12 months	Any grade - 89%; Grade 3 or 4 - 24% Median time to onset - 5 days Median duration - 7.5 days Tocilizumab use - 80%; Glucocorticoid use - 75% Vasopressor use - 40%	Any grade - 60%; Grade 3 or higher - 25% Median time to onset - 9 days Median duration - 7 days	Grade 3 or higher cytopenia's (76%) and infections (25%)
Yescarta	ZUMA-1	ORR - 82% per protocol, 82% ITT; CR - 52% per protocol, 54% ITT Median DOR - 8.1 months at 6 months, 11.1 months at 12 months PFS - 5.8 months at 12 months, 49% at 15 months OS - 78% at 6 months, 59% at 12 months, 52% at 18 months	Any grade - 93%; Grade 3 or higher - 13% Median time to onset - 2 days Median duration - 8 days Tocilizumab use - 43%; Glucocorticoid use - 27% Vasopressor use - 17%	Any grade - 64%; Grade 3 or higher - 28% Median time to onset - 5 days Median duration - 17 days	Grade 3 or higher neutropenia (78%), anemia (43%), and thrombocytopenia (38%)
	ZUMA-5	ORR - 92% (FL 94%, MZL 85%); CR - 76% (FL 80%, MZL 60%) Median DOR - not reached; estimated 72% at 12 months PFS - not reached; estimated 74% at 12 months OS - not reached; estimated 93% at 12 months	Grade 3 or higher - 7% (FL 6%, MZL 9%)	Grade 3 or higher - 19% (FL 15%, MZL 41%)	Neutropenia (33%), decreased neutrophil count (27%), and anemia (23%)

Key: ORR: Overall Response Rate; CR: Complete Response; DOR: Duration of Response; PFS: Progression Free Survival; OS: Overall Survival; RFS: Relapse Free Survival